The collaboration is in line with Orexo’s strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera’s innovative vaccine platform. The AmorphOX technology has…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.